Full-Time

Senior Paralegal

Posted on 4/11/2024

Cytokinetics

Cytokinetics

501-1,000 employees

Develops drugs for muscle function disorders

Compensation Overview

$131k - $160k/yr

Expert

San Bruno, CA, USA

Requires onsite presence in South San Francisco, California for a minimum of three days per week.

Category
Contract Management
Legal & Compliance
Required Skills
Communications
Word/Pages/Docs
PowerPoint/Keynote/Slides
Requirements
  • BA/BS degree or Paralegal certificate with 10+ years of experience as a paralegal with diverse complex transactional experience
  • Experience in biotechnology/pharmaceutical industry required
  • Excellent written and verbal communication skills, analytical skills, attention to detail, and ability to appropriately prioritize competing demands
  • Demonstrated ability to work independently and collaboratively within a legal team to ensure timely and accurate provision of legal services across the company
  • Excellent abilities with relevant software applications (e.g., Microsoft Word, Outlook, Excel, PowerPoint, and DocuSign)
  • Proficient in the use of contract management systems
  • Excellent interpersonal skills with the ability to interact and collaborate with business persons as well as internal and external lawyers, other paralegals, and support personnel
  • Provide a wide variety of organizational, investigative, administrative, and analytical support and assistance to the Legal Department
  • Exercises judgment within generally defined practices and policies in selecting methods and techniques for obtaining solutions
  • Experience supporting Clinical Trial Operations matters is a plus
  • Minimum of 3 onsite days a week in SSF
Responsibilities
  • Partner with internal clients to prepare certain agreements and flag issues for attorney review when needed
  • Communicate the advice of Legal department to businesses to manage legal risks
  • Manage contract workflow and approval process, including verifying that internal requirements are met, monitoring status, securing signatures, etc.
  • Draft, review, analyze and negotiate standard contracts (e.g., non-disclosure agreements, consulting agreements, clinical trial agreements, services agreements, work orders under master services agreements, license agreements, etc.)
  • Use the online contract management system and act as the first point of contact for user questions
  • Own standard contract templates and playbook database for allocated businesses and maintain and recommend updates as needed
  • Work with the attorneys on special projects
  • Draft and maintain correspondence and diligence materials

Cytokinetics focuses on developing medicines that improve muscle function for patients with cardiovascular and neuromuscular diseases. Their products are small molecule drugs designed to either enhance or inhibit muscle function, tailored to specific therapeutic needs. The company has a pipeline of drugs, including omecamtiv mecarbil and reldesemtiv, which are in various stages of clinical trials. Unlike many competitors, Cytokinetics emphasizes rigorous scientific research and has conducted over 50 clinical trials to ensure the effectiveness of its treatments. The goal of Cytokinetics is to bring new therapies to market that address the unmet needs of patients suffering from conditions like heart failure, ALS, and HCM.

Company Size

501-1,000

Company Stage

IPO

Headquarters

South San Francisco, California

Founded

1998

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA fast-track designation could expedite approval for Cytokinetics' pipeline products.
  • Digital health tools enhance patient monitoring, supporting Cytokinetics' clinical trials.
  • Telemedicine expands clinical trial reach, benefiting Cytokinetics' recruitment efforts.

What critics are saying

  • Increased competition from Imbria Pharmaceuticals may impact Cytokinetics' market share.
  • Sanofi's rights to Aficamten in China could affect Cytokinetics' global expansion plans.
  • Reliance on clinical trial outcomes could impact investor confidence if results are unfavorable.

What makes Cytokinetics unique

  • Cytokinetics focuses on muscle activators and inhibitors for cardiovascular and neuromuscular diseases.
  • The company has a robust pipeline including omecamtiv mecarbil and aficamten.
  • Cytokinetics collaborates with tech firms to accelerate drug discovery processes.

Help us improve and share your feedback! Did you find this helpful?

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

-1%
GlobeNewswire
May 8th, 2025
Cytokinetics Announces Four Upcoming Presentations At The European Society Of Cardiology Heart Failure 2025 Congress

SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three Late Breaking Science presentations and one ePoster presentation at Heart Failure 2025, an International Congress of the European Society of Cardiology, taking place in Belgrade, Serbia from May 17, 2025 – May 20, 2025.Late Breaking Science PresentationsTitle: Efficacy and Safety of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy and Mild SymptomsPresenter: Iacopo Olivotto, M.D., Professor of Cardiology at the University of Florence, Head of Cardiology at Meyer Children's Hospital, Florence, ItalyDate: May 17, 2025Topic: Chronic Heart FailureSession Title: Late Breaking Science in Heart Failure, Cardiomyopathies, Pulmonary Hypertension and Valvular Heart DiseaseSession Type: Late Breaking ScienceSession Time: 4:00 - 5:00 PM CESTPresentation Time: 4:20 PM CESTLocation: Room 1Title: SEQUOIA-HCM: Effect of Aficamten Treatment on Patients with Hypertrophic Obstructive Cardiomyopathy by Geographical RegionPresenter: Caroline Coats, M.D., Ph.D., Lead Clinician, West of Scotland Inherited Cardiac Conditions Service, Honorary Senior Lecturer, School of Cardiovascular and Metabolic Health, University of GlasgowDate: May 18, 2025Topic: Chronic Heart FailureSession Title: Hottest Trials and Trial Updates (2)Session Type: Late Breaking ScienceSession Time: 10:45 AM - 12:15 PM CESTPresentation Time: 11:11 AM CESTLocation: Room 1Title: The Effect of Omecamtiv Mecarbil on Outcomes Analyzed Using the Win Ratio: An Exploratory Analysis of GALACTIC-HFPresenter: Kieran F. Docherty, Ph.D., Clinical Senior Lecturer in Heart Failure and Clinical Trials and Honorary Consultant Cardiologist, University of GlasgowDate: May 19, 2025Topic: PharmacotherapySession Title: Clinical Trials Updates in Medical TherapySession Type: Late Breaking ScienceSession Time: 1:45 PM - 2:45 PM CESTPresentation Time: 2:25 PM CESTLocation: Room 1ePoster PresentationTitle: Associations Between Age and Sex and Cardiovascular Outcomes in Patients with Non-Obstructive Hypertrophic CardiomyopathyPresenter: Paulos Gebrehiwet, Ph.D., M.S., Senior Manager, Health Economics and Outcomes Research, CytokineticsDate: May 17, 2025Topic: ClinicalSession Title: ePosters in Myocardial Disease (2)Session Type: ePostersSession Time: 9:00 AM - 5:00 PM CESTPresentation Time: 1:26 PM CESTLocation: ePosters Screen 14 - Research GatewayAbout CytokineticsCytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology to advance a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics is readying for potential regulatory approvals and commercialization of aficamten, a cardiac myosin inhibitor following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten, for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.Forward-Looking StatementsThis press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements

GlobeNewswire
Apr 10th, 2025
Imbria Pharmaceuticals Raises $57.5M Series B Financing Round and Appoints Alvin Shih, MD as CEO

– Led by new investor Deep Track Capital, with participation from AN Ventures, Catalio Capital Management, Cytokinetics, Inc. and existing investors RA...

Here Novi
Mar 21st, 2025
Cytokinetics Launches EARTH-HCM for Hypertrophic Cardiomyopathy Awareness

Cytokinetics launches EARTH-HCM for hypertrophic cardiomyopathy awareness.

Investing.com
Mar 20th, 2025
Cytokinetics launches interactive HCM public health tool

Cytokinetics launches interactive HCM public health tool.

Medical Update Online
Mar 19th, 2025
Cytokinetics to present new findings on Aficamten and hypertrophic cardiomyopathy at ACC 2025

Cytokinetics to present new findings on Aficamten and hypertrophic cardiomyopathy at ACC 2025.

INACTIVE